RNAZ — TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 7
- Website: https://www.transcodetherapeutics.com
Latest SEC filings for RNAZ
- 3 — 2026-09-21
- 10-Q — 2026-08-14
- 8-K — 2026-08-03
- SCHEDULE 13G — 2026-07-28
- SCHEDULE 13D/A — 2026-07-27
- SCHEDULE 13D/A — 2026-07-23
- 8-K — 2026-07-20
- 424B3 — 2026-07-20
- 424B3 — 2026-07-20
- SCHEDULE 13D/A — 2026-07-17
Latest RNAZ news
- — Natera Partners With TransCode to Advance Colorectal Cancer Trial (Zacks Investment Research)
- — TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up (prnewswire.com)
Educational tool only — not investment advice.